| 000 | 01830 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516055913.0 | ||
| 264 | 0 | _c20120502 | |
| 008 | 201205s 0 0 eng d | ||
| 022 | _a1532-0987 | ||
| 024 | 7 |
_a10.1097/INF.0b013e318235455b _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aResch, Bernhard | |
| 245 | 0 | 0 |
_aCost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. _h[electronic resource] |
| 260 |
_bThe Pediatric infectious disease journal _cJan 2012 |
||
| 300 |
_ae1-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xeconomics |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xeconomics |
| 650 | 0 | 4 |
_aAustria _xepidemiology |
| 650 | 0 | 4 | _aChemoprevention |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aDecision Trees |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHospitalization |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 | _aInfant, Premature |
| 650 | 0 | 4 |
_aInfant, Premature, Diseases _xepidemiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPalivizumab |
| 650 | 0 | 4 |
_aRespiratory Syncytial Virus Infections _xepidemiology |
| 650 | 0 | 4 |
_aRespiratory Syncytial Viruses _xdrug effects |
| 650 | 0 | 4 |
_aRespiratory Tract Infections _xepidemiology |
| 650 | 0 | 4 | _aRisk |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSommer, Constanze | |
| 700 | 1 | _aNuijten, Mark J C | |
| 700 | 1 | _aSeidinger, Susanne | |
| 700 | 1 | _aWalter, Evelyn | |
| 700 | 1 | _aSchoellbauer, Vera | |
| 700 | 1 | _aMueller, Wilhelm D | |
| 773 | 0 |
_tThe Pediatric infectious disease journal _gvol. 31 _gno. 1 _gp. e1-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/INF.0b013e318235455b _zAvailable from publisher's website |
| 999 |
_c21196848 _d21196848 |
||